In conclusion, we identified the indole‐containing small molecules as candidates of orally deliverable anti‐osteoporosis agents, activating the Wnt/β‐catenin signaling via inhibition of Dvl–CXXC5 interaction. The gene discussed is DVL1; the disease is osteoporosis.